Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS
Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)Market opportunity estimated to be greater than US$1 billionKey highlights- Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in